[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1988

Phenelzine vs Placebo in 50 Patients With Bulimia

Author Affiliations

From The New York State Psychiatric Institute and the College of Physicians & Surgeons, Columbia University, New York.

Arch Gen Psychiatry. 1988;45(5):471-475. doi:10.1001/archpsyc.1988.01800290091011
Abstract

• To examine the efficacy of the monoamine oxidase inhibitor phenelzine sulfate in the treatment of bulimia, a doubleblind, placebo-controlled trial was conducted. In 50 women who completed the trial, phenelzine was significantly superior to placebo in the reduction of binge frequency (64% vs 5%), in the fraction of patients who had ceased bingeing at the end of the trial (35% vs 4%), and in several measures of psychological state. The superiority of phenelzine over placebo was not confined to a depressed subgroup of patients. Although no patient experienced a hypertensive crisis during the study, other side effects of phenelzine were problematic and limit the usefulness of phenelzine in this population.

×